Shire has 15 years of experience in providing treatment for Fabry disease

As one of the world's leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives.

Choose Your Country

The information on this website is intended only to provide information about Replagal (agalsidase alfa). This information should not be used in place of advice from your GP or other healthcare professional. These web pages are not intended for residents of the United States.

This website has been produced by Shire Human Genetic Therapies, a business within the Shire group of companies. The website has been developed in accordance with industry and legal standards to provide information for the general public, patients and their families, and also healthcare professionals about Replagal. Shire Human Genetic Therapies makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive. References for published sources of information cited on the Replagal website have been provided on the relevant pages.

Sponsored by Shire Human Genetic Therapies.
UK Offices: Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP.

Email: HGTmedcomm@shire.com